Christopher Fuller, MD
Ophthalmology · Lubbock, TXNPI 1790830032
Payments from drug & device makers
Across 350 payments — averaging $295.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$33K
- Novartis$20K
- Alimera Sciences, Inc.$20K
- Genentech USA, Inc.$12K
- Alcon$5K
- Alcon Research LLC$3K
- plus $10K from 26 others
Across 3 payments — averaging $717.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alimera Sciences, Inc.$2K
What the payments were for
- Consulting fees$33,99947%
- Speaking & faculty fees$24,00233%
- Travel & lodging$2,5374%
- Food & beverage$11,02715%
- Education$1080%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 47 | $33,441 |
| Novartis | 23 | $20,028 |
| Alimera Sciences, Inc. | 41 | $19,508 |
| Genentech USA, Inc. | 39 | $11,981 |
| Alcon | 27 | $5,119 |
| Alcon Research LLC | 3 | $3,100 |
| Apellis Pharmaceuticals, Inc. | 16 | $3,057 |
| Bausch & Lomb Americas Inc. | 17 | $1,384 |
| Dutch Ophthalmic, USA | 4 | $1,070 |
| Regeneron Healthcare Solutions, Inc. | 37 | $882 |
| Genentech, Inc. | 1 | $765 |
| Johnson & Johnson Surgical Vision, Inc. | 15 | $558 |
| ANI Pharmaceuticals, Inc. | 14 | $346 |
| Astellas Pharma US Inc | 7 | $269 |
| Glaukos Corporation | 4 | $258 |
| Mallinckrodt Hospital Products Inc. | 3 | $219 |
| Regeneron | 2 | $198 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $196 |
| Ocular Therapeutix, Inc. | 10 | $186 |
| Optos, Inc. | 3 | $175 |
| Eyepoint US, Inc. | 5 | $157 |
| Harrow Eye, LLC | 6 | $113 |
| Pfizer | 5 | $102 |
| Sandoz | 4 | $95 |
| Ivantis, Inc | 1 | $78 |
| Coherus Oncology, Inc. | 4 | $75 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Eyevance Pharmaceuticals LLC | 3 | $53 |
| Sun Pharmaceutical Industries Inc. | 2 | $30 |
| Biogen | 1 | $23 |
| LEO Pharma Inc. | 1 | $19 |
| Spark Therapeutics, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Iluvien$18,336
- BEOVU$14,400
- Lucentis$6,057
- SUSVIMO$5,861
- Constellation$3,869
- NGENUITY$3,213
- YUTIQ$1,390
- EVA, combined machine$962
- TISSUEBLUE$962
- VABYSMO$871
- XIPERE$800
- OZURDEX$750
- Luxor$490
- EYLEA HD$226
- Syfovre$153
- AcrySof IQ PanOptix UV IOL$146
- Unity$134
- EYLEA$124
- Izervay$121
- AcrySof IQ PanOptix$110
How this compares
$103,573 in reported general payments places this provider in the 90th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 22 | $17,341 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 241 | $9,843 |
| ProlensaBromfenac Sodium | 25 | $8,599 |
| Tobradex StTobramycin/Dexamethasone | 36 | $8,403 |
| VyzultaLatanoprostene Bunod | 14 | $5,792 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 17 | $3,267 |
| Bromfenac Sodium | 16 | $2,918 |
| Loteprednol Etabonate | 12 | $1,626 |
| FlarexFluorometholone Acetate | 13 | $1,576 |
| Brimonidine Tartrate | 39 | $894 |
| Prednisolone Acetate | 27 | $822 |
| Dorzolamide Hcl | 41 | $618 |
| Acetazolamide | 18 | $502 |
| Latanoprost | 75 | $461 |
| Timolol Maleate | 40 | $204 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $1,384 | $23,13236 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $196 | $10,22537 claims |
| Eyevance Pharmaceuticals LLCTobradex St, Flarex | $53 | $9,97949 claims |
| AlconSimbrinza | $5,119 | $3,26717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Lubbock
- Charles WykoffBellaire$73.4M
- David BrownHouston$51.7M
- Sunil PatelAbilene$11.1M
- Chirag JhaveriAustin$9.4M
- Robert WongAustin$6.6M
- Fuad MakkoukAustin$6.6M
- Patrick WilliamsArlington$6.6M
- Ashkan AbbeyDallas$5.7M
- Karl CsakyDallas$4.9M
- Michael SingerSan Antonio$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.